{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:24:35Z","timestamp":1762543475447,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016623","name":"Radiation Oncology Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016623","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.clbc.2021.07.013","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T12:05:02Z","timestamp":1627387502000},"page":"e65-e73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Incidence and Severity of Myelosuppression With Palbociclib After Palliative Bone Radiation in Advanced Breast Cancer: A Single Center Experience and Review of Literature"],"prefix":"10.1016","volume":"22","author":[{"given":"Haval","family":"Norman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberley T.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vered","family":"Stearns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara R.","family":"Alcorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha S.","family":"Mangini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2021.07.013_bib0001","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0142","article-title":"Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4\/6 inhibitors in breast cancer: practical considerations and recommendations","volume":"22","author":"Spring","year":"2017","journal-title":"Oncologist"},{"year":"2019","author":"Ibrance (palbociclib) Tablets [Prescribing Information]","key":"10.1016\/j.clbc.2021.07.013_bib0002"},{"year":"2018","author":"Kisqali (ribociclib) Tablets [Prescribing Information]","key":"10.1016\/j.clbc.2021.07.013_bib0003"},{"year":"2019","author":"Verzenio (abemaciclib) Tablets [Prescribing Information]","key":"10.1016\/j.clbc.2021.07.013_bib0004"},{"key":"10.1016\/j.clbc.2021.07.013_bib0005","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2019","journal-title":"JAMA Oncol"},{"issue":"suppl 4","key":"10.1016\/j.clbc.2021.07.013_bib0006","article-title":"Abstract P1-19-02: Overall survival for first-line palbociclib plus letrozole vs letrozole alone for HR+\/HER2- metastatic breast cancer patients in US real-world clinical practice","volume":"80","author":"DeMichele","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2021.07.013_bib0007","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2021.07.013_bib0008","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2021.07.013_bib0009","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2021.07.013_bib0010","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1634\/theoncologist.2016-0097","article-title":"Palbociclib in combination with fulvestrant in women with hormone receptor-positive\/HER2-negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3)","volume":"21","author":"Verma","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2021.07.013_bib0011","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2021.07.013_bib0012","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","article-title":"MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, n patients with refractory HR+\/HER2- metastatic breast cancer","volume":"23","author":"Dickler","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2021.07.013_bib0013","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2021.07.013_bib0014","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-016-0721-5","article-title":"Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: Expanded analyses of subgroups from the randomized pivotal trial PALOMA-1\/TRIO-18","volume":"18","author":"Finn","year":"2016","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2021.07.013_bib0015","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast Cncer","volume":"382","author":"Slamon","year":"2019","journal-title":"N Engl J Med"},{"issue":"suppl 18","key":"10.1016\/j.clbc.2021.07.013_bib0016","article-title":"Phase III MONALEESA-7 trial of premenopausal patients with HR+\/HER2\u2212 advanced breast cancer (ABC) treated with endocrine therapy \u00b1 ribociclib: Overall survival (OS) results","volume":"37","author":"Hurvitz","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2021.07.013_bib0017","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.cell.2004.08.002","article-title":"Mammalian cells cycle without the D-type cyclin-dependent kinases CDK4 and CDK6","volume":"118","author":"Malumbres","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.clbc.2021.07.013_bib0018","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/blood-2014-06-584417","article-title":"CDK6 as a key regulator of hematopoietic and leukemic stem cell activation","volume":"125","author":"Scheicher","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clbc.2021.07.013_bib0019","doi-asserted-by":"crossref","first-page":"69493","DOI":"10.18632\/oncotarget.17778","article-title":"Preclinical characterization of abemaciclib in hormone receptor positive breast cancer","volume":"8","author":"Torres-Guzm\u00e1n","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clbc.2021.07.013_bib0020","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1148\/83.6.1084","article-title":"The effects of varying dosages of irradiation upon sternal-marrow regeneration","volume":"83","author":"Sykes","year":"1964","journal-title":"Radiology"},{"key":"10.1016\/j.clbc.2021.07.013_bib0021","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/1097-0142(196409)17:9<1144::AID-CNCR2820170907>3.0.CO;2-4","article-title":"Long-term effects of therapeutic irradiation upon bone marrow","volume":"17","author":"Sykes","year":"1964","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2021.07.013_bib0022","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.breast.2019.05.001","article-title":"Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: preliminary assessment of toxicity","volume":"46","author":"Ippolito","year":"2019","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2021.07.013_bib0023","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djy109","article-title":"Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for HR1\/HER2- advanced breast cancer","volume":"111","author":"Di\u00e9ras","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2021.07.013_bib0024","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0.; 2017. 1-147. Available at: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed: August 22, 2019. Published November 27, 2017."},{"key":"10.1016\/j.clbc.2021.07.013_bib0025","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2020.38.15_suppl.562","article-title":"Impact of metastases directed radiation therapy on CDK4\/6 inhibitors dose reduction and treatment discontinuation for metastatic HR+\/HER2- breast cancer (MBC)","volume":"38","author":"Meattini","year":"2020","journal-title":"J Clin Oncol"},{"year":"2001","series-title":"Medical Management of Radiation Accidents: Manual on the Acute Radiation Syndrome","author":"Fliedner","key":"10.1016\/j.clbc.2021.07.013_bib0026"},{"key":"10.1016\/j.clbc.2021.07.013_bib0027","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.radonc.2015.11.020","article-title":"Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation","volume":"118","author":"Sini","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clbc.2021.07.013_bib0028","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijrobp.2020.02.633","article-title":"Radiation-induced lymphopenia predicts poorer prognosis in patients with breast cancer: a post hoc analysis of a randomized controlled trial of postmastectomy hypofractionated radiation therapy","volume":"108","author":"Sun","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clbc.2021.07.013_bib0029","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.clbc.2020.05.013","article-title":"Cyclin-dependent kinase 4\/6 inhibitors combined with radiotherapy for patients with metastatic breast cancer","volume":"20","author":"Ratosa","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2021.07.013_bib0030","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.adro.2019.03.011","article-title":"Safety and efficacy of palbociclib and radiation therapy in patients with metastatic breast cancer: initial results of a novel combination","volume":"4","author":"Chowdhary","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.clbc.2021.07.013_bib0031","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ijrobp.2009.11.040","article-title":"Distribution of proliferating bone marrow in adult cancer patients determined using FLT-PET imaging","volume":"79","author":"Hayman","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clbc.2021.07.013_bib0032","unstructured":"Torres M. Radiation therapy, palbociclib, and hormone therapy in treating breast cancer patients with bone metastasis (ASPIRE). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03691493?term=nct03691493&draw=1&rank=1. Accessed: March 8, 2021."},{"key":"10.1016\/j.clbc.2021.07.013_bib0033","unstructured":"Jeong J. Local treatment in ER-positive\/HER2-negative oligo-metastatic breast cancer (CLEAR). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03750396?cond=nct03750396&draw=2&rank=1. Accessed: December 8, 2021."}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820921002020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820921002020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:22:05Z","timestamp":1761513725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820921002020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1526820921002020"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2021.07.013","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence and Severity of Myelosuppression With Palbociclib After Palliative Bone Radiation in Advanced Breast Cancer: A Single Center Experience and Review of Literature","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2021.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}